journal
MENU ▼
Read by QxMD icon Read
search

Lancet Neurology

journal
https://read.qxmd.com/read/31519472/new-evidence-on-the-management-of-lewy-body-dementia
#1
REVIEW
John-Paul Taylor, Ian G McKeith, David J Burn, Brad F Boeve, Daniel Weintraub, Claire Bamford, Louise M Allan, Alan J Thomas, John T O'Brien
Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish...
September 10, 2019: Lancet Neurology
https://read.qxmd.com/read/31501026/anne-cross-it-s-a-family-affair
#2
Adrian Burton
No abstract text is available yet for this article.
September 6, 2019: Lancet Neurology
https://read.qxmd.com/read/31494011/epilepsy-genetics-clinical-impacts-and-biological-insights
#3
REVIEW
Colin A Ellis, Slavé Petrovski, Samuel F Berkovic
Genomics now has an increasingly important role in neurology clinics. Regarding the epilepsies, innovations centred around technology, analytics, and collaboration have led to remarkable progress in gene discovery and have revealed the diverse array of genetic mechanisms and neurobiological pathways that contribute to these disorders. The new genomic era can present a challenge to clinicians, who now find themselves asked to interpret and apply genetic data to their daily management of patients with epilepsy...
September 4, 2019: Lancet Neurology
https://read.qxmd.com/read/31494010/epilepsy-genetics-and-the-precision-medicine-matrix
#4
Sanjay M Sisodiya
No abstract text is available yet for this article.
September 4, 2019: Lancet Neurology
https://read.qxmd.com/read/31494009/dementia-in-china-epidemiology-clinical-management-and-research-advances
#5
REVIEW
Longfei Jia, Meina Quan, Yue Fu, Tan Zhao, Yan Li, Cuibai Wei, Yi Tang, Qi Qin, Fen Wang, Yuchen Qiao, Shengliang Shi, Yan-Jiang Wang, Yifeng Du, Jiewen Zhang, Junjian Zhang, Benyan Luo, Qiumin Qu, Chunkui Zhou, Serge Gauthier, Jianping Jia
China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home...
September 4, 2019: Lancet Neurology
https://read.qxmd.com/read/31492653/another-sphingosine-1-phosphate-receptor-modulator-for-the-treatment-of-patients-with-multiple-sclerosis
#6
Ellen M Mowry, John R Corboy
No abstract text is available yet for this article.
September 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31492652/safety-and-efficacy-of-ozanimod-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis-radiance-a-multicentre-randomised-24-month-phase-3-trial
#7
Jeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree, James K Sheffield, Neil Minton, Kartik Raghupathi, Vivian Huang, Ludwig Kappos
BACKGROUND: Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI measures and was well tolerated. The RADIANCE phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis...
September 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31492651/safety-and-efficacy-of-ozanimod-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis-sunbeam-a-multicentre-randomised-minimum-12-month-phase-3-trial
#8
Giancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree, James K Sheffield, Neil Minton, Kartik Raghupathi, Ning Ding, Jeffrey A Cohen
BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety profile, in participants with relapsing multiple sclerosis. The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis. METHODS: SUNBEAM was a randomised, double-blind, double-dummy, active-controlled phase 3 trial done at 152 academic medical centres and clinical practices in 20 countries...
September 3, 2019: Lancet Neurology
https://read.qxmd.com/read/31451409/association-between-plasma-gfap-concentrations-and-mri-abnormalities-in-patients-with-ct-negative-traumatic-brain-injury-in-the-track-tbi-cohort-a-prospective-multicentre-study
#9
John K Yue, Esther L Yuh, Frederick K Korley, Ethan A Winkler, Xiaoying Sun, Ross C Puffer, Hansen Deng, Winward Choy, Ankush Chandra, Sabrina R Taylor, Adam R Ferguson, J Russell Huie, Miri Rabinowitz, Ava M Puccio, Pratik Mukherjee, Mary J Vassar, Kevin K W Wang, Ramon Diaz-Arrastia, David O Okonkwo, Sonia Jain, Geoffrey T Manley
BACKGROUND: After traumatic brain injury (TBI), plasma concentration of glial fibrillary acidic protein (GFAP) correlates with intracranial injury visible on CT scan. Some patients with suspected TBI with normal CT findings show pathology on MRI. We assessed the discriminative ability of GFAP to identify MRI abnormalities in patients with normal CT findings. METHODS: TRACK-TBI is a prospective cohort study that enrolled patients with TBI who had a clinically indicated head CT scan within 24 h of injury at 18 level 1 trauma centres in the USA...
August 23, 2019: Lancet Neurology
https://read.qxmd.com/read/31451408/should-plasma-gfap-guide-the-management-of-patients-with-traumatic-brain-injury-and-a-negative-ct-scan
#10
Fiona Lecky
No abstract text is available yet for this article.
August 23, 2019: Lancet Neurology
https://read.qxmd.com/read/31444143/blood-pressure-control-as-an-intervention-to-prevent-dementia
#11
Lenore J Launer
No abstract text is available yet for this article.
August 20, 2019: Lancet Neurology
https://read.qxmd.com/read/31444142/associations-between-blood-pressure-across-adulthood-and-late-life-brain-structure-and-pathology-in-the-neuroscience-substudy-of-the-1946-british-birth-cohort-insight-46-an-epidemiological-study
#12
Christopher A Lane, Josephine Barnes, Jennifer M Nicholas, Carole H Sudre, David M Cash, Thomas D Parker, Ian B Malone, Kirsty Lu, Sarah-Naomi James, Ashvini Keshavan, Heidi Murray-Smith, Andrew Wong, Sarah M Buchanan, Sarah E Keuss, Elizabeth Gordon, William Coath, Anna Barnes, John Dickson, Marc Modat, David Thomas, Sebastian J Crutch, Rebecca Hardy, Marcus Richards, Nick C Fox, Jonathan M Schott
BACKGROUND: Midlife hypertension confers increased risk for cognitive impairment in late life. The sensitive period for risk exposure and extent that risk is mediated through amyloid or vascular-related mechanisms are poorly understood. We aimed to identify if, and when, blood pressure or change in blood pressure during adulthood were associated with late-life brain structure, pathology, and cognition. METHODS: Participants were from Insight 46, a neuroscience substudy of the ongoing longitudinal Medical Research Council National Survey of Health and Development, a birth cohort that initially comprised 5362 individuals born throughout mainland Britain in one week in 1946...
August 20, 2019: Lancet Neurology
https://read.qxmd.com/read/31405713/mri-in-traumatic-spinal-cord-injury-from-clinical-assessment-to-neuroimaging-biomarkers
#13
REVIEW
Patrick Freund, Maryam Seif, Nikolaus Weiskopf, Karl Friston, Michael G Fehlings, Alan J Thompson, Armin Curt
Traumatic spinal cord injury occurs when an external physical impact damages the spinal cord and leads to permanent neurological dysfunction and disability, and it is associated with a high socioeconomic burden. Conventional MRI plays a crucial role in the diagnostic workup as it reveals extrinsic compression of the spinal cord and disruption of the discoligamentous complex. Additionally, it can reveal macrostructural evidence of primary intramedullary damage such as haemorrhage, oedema, post-traumatic cystic cavities, and tissue bridges...
August 9, 2019: Lancet Neurology
https://read.qxmd.com/read/31401076/antithrombotics-and-bleeding-risk-paradoxical-findings
#14
Eric E Smith
No abstract text is available yet for this article.
August 6, 2019: Lancet Neurology
https://read.qxmd.com/read/31401075/long-term-antithrombotic-therapy-and-risk-of-intracranial-haemorrhage-from-cerebral-cavernous-malformations-a-population-based-cohort-study-systematic-review-and-meta-analysis
#15
Susanna M Zuurbier, Charlotte R Hickman, Christos S Tolias, Leon A Rinkel, Rebecca Leyrer, Kelly D Flemming, David Bervini, Giuseppe Lanzino, Robert J Wityk, Hans-Martin Schneble, Ulrich Sure, Rustam Al-Shahi Salman
BACKGROUND: Antithrombotic (anticoagulant or antiplatelet) therapy is withheld from some patients with cerebral cavernous malformations, because of uncertainty around the safety of these drugs in such patients. We aimed to establish whether antithrombotic therapy is associated with an increased risk of intracranial haemorrhage in adults with cerebral cavernous malformations. METHODS: In this population-based, cohort study, we used data from the Scottish Audit of Intracranial Vascular Malformations, which prospectively identified individuals aged 16 years and older living in Scotland who were first diagnosed with a cerebral cavernous malformation during 1999-2003 or 2006-10...
August 6, 2019: Lancet Neurology
https://read.qxmd.com/read/31377012/hereditary-spastic-paraplegia-from-diagnosis-to-emerging-therapeutic-approaches
#16
REVIEW
Samuel Shribman, Evan Reid, Andrew H Crosby, Henry Houlden, Thomas T Warner
Hereditary spastic paraplegia (HSP) describes a heterogeneous group of genetic neurodegenerative diseases characterised by progressive spasticity of the lower limbs. The pathogenic mechanism, associated clinical features, and imaging abnormalities vary substantially according to the affected gene and differentiating HSP from other genetic diseases associated with spasticity can be challenging. Next generation sequencing-based gene panels are now widely available but have limitations and a molecular diagnosis is not made in most suspected cases...
July 31, 2019: Lancet Neurology
https://read.qxmd.com/read/31375367/do-we-have-equipoise-when-it-comes-to-how-we-treat-active-multiple-sclerosis
#17
Gavin Giovannoni
No abstract text is available yet for this article.
July 30, 2019: Lancet Neurology
https://read.qxmd.com/read/31375366/early-highly-effective-versus-escalation-treatment-approaches-in-relapsing-multiple-sclerosis
#18
REVIEW
Daniel Ontaneda, Emma Tallantyre, Tomas Kalincik, Sarah M Planchon, Nikos Evangelou
Treatment decisions in multiple sclerosis are complex given the large number of disease-modifying therapies with diverse safety and efficacy profiles. The importance of early treatment has been recognised but how intensively to treat at onset is not known. Substantial variability exists in treatment selection with weak clinical trial evidence to guide initial treatment choices. Decision-making is made more complicated by variable tolerance for risk of side-effects and inability to accurately predict treatment response...
July 30, 2019: Lancet Neurology
https://read.qxmd.com/read/31345666/world-brain-day-2019-migraine-the-painful-truth
#19
LETTER
Tissa Wijeratne, Wolfgang Grisold, David Dodick, William Carroll
No abstract text is available yet for this article.
July 22, 2019: Lancet Neurology
https://read.qxmd.com/read/31326280/an-update-on-anti-nmda-receptor-encephalitis-for-neurologists-and-psychiatrists-mechanisms-and-models
#20
REVIEW
Josep Dalmau, Thais Armangué, Jesús Planagumà, Marija Radosevic, Francesco Mannara, Frank Leypoldt, Christian Geis, Eric Lancaster, Maarten J Titulaer, Myrna R Rosenfeld, Francesc Graus
The identification of anti-NMDA receptor (NMDAR) encephalitis about 12 years ago made it possible to recognise that some patients with rapidly progressive psychiatric symptoms or cognitive impairment, seizures, abnormal movements, or coma of unknown cause, had an autoimmune disease. In this disease, autoantibodies serve as a diagnostic marker and alter NMDAR-related synaptic transmission. At symptom onset, distinguishing the disease from a primary psychiatric disorder is challenging. The severity of symptoms often requires intensive care...
July 17, 2019: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"